We use cookies to offer you a better browsing experience, including personalized advertising. By continuing to use the site you agree to their use.

Skip to main content Skip to section navigation Skip to footer
  • HOME
  • CONTACT US
  • Who We Are
    • Our Story
    • Corporate History
    • Stock Price History
    • Settlement Key Features
    • Growth Strategy
    • Our Patents
  • Leadership
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Committees
  • Pipeline
    • OVERVIEW
    • BASAL CELL CARCINOMA NEVUS SYNDROME
      • WHAT IS BCCNS
      • BCCNS’ UNMET NEED
      • TREATMENT OF BCCNS WITH ITRACONAZOLE
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
    • LUNG CANCER
      • NON-SMALL CELL LUNG CANCER
      • ITRACONAZOLE IN NSCLC
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
    • PROSTATE CANCER
      • METASTATIC, CASTRATE-RESISTANT PROSTATE CANCER
      • ITRACONAZOLE IN mCRPC
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
  • Investors & Media
    • Overview
    • News & Events
      • Press Releases
      • IR Calendar
      • Presentations
      • Email Alerts
    • Company Info
      • Company Profile
      • Executive Team
      • Scientific Advisory Board
      • Contacts
      • FAQ
    • Financial Info
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote and Chart
      • Historical Data
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • At-a-Glance
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Who We Are
    • Our Story
    • Corporate History
    • Stock Price History
    • Settlement Key Features
    • Growth Strategy
    • Our Patents
  • Leadership
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Committees
  • Pipeline
    • OVERVIEW
    • BASAL CELL CARCINOMA NEVUS SYNDROME
      • WHAT IS BCCNS
      • BCCNS’ UNMET NEED
      • TREATMENT OF BCCNS WITH ITRACONAZOLE
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
    • LUNG CANCER
      • NON-SMALL CELL LUNG CANCER
      • ITRACONAZOLE IN NSCLC
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
    • PROSTATE CANCER
      • METASTATIC, CASTRATE-RESISTANT PROSTATE CANCER
      • ITRACONAZOLE IN mCRPC
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
  • Investors & Media
    • Overview
    • News & Events
      • Press Releases
      • IR Calendar
      • Presentations
      • Email Alerts
    • Company Info
      • Company Profile
      • Executive Team
      • Scientific Advisory Board
      • Contacts
      • FAQ
    • Financial Info
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote and Chart
      • Historical Data
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • At-a-Glance
      • Board of Directors
      • Board Committees
      • Governance Documents

Quote and Chart

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Company Profile
    • Executive Team
    • Scientific Advisory Board
    • Contacts
    • FAQ
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote and Chart
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • At-a-Glance
    • Board of Directors
    • Board Committees
    • Governance Documents

  • Stock Data

  • Quote and Chart
  • Historical Data
  • accessibilityAccessibility Statement
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
Inhibitor-Therapeutics

900 W Platt St
Suite 200
Tampa, FL 33606

Our Mission

Inhibitor Therapeutics, Inc. (“INHIBITOR”) is a pharmaceutical development company focused on developing and commercializing innovative therapies based on already approved active pharmaceutical ingredients for novel, clinically valuable, and patent-protected indications. Our lead product is itraconazole for a hereditary, cancer syndrome (Gorlin’s syndrome) which is an orphan disease.

  • Home
  • Who We Are
  • Pipeline
  • Investors & Media
  • Contact Us
  • Terms of Use and Privacy Policy

Copyright 2025 Inhibitor Therapeutics, Inc.

Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.